[1]
|
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E. and Heikenwalder, M. (2018) The Immunology of Hepatocellular Carcinoma. Nature Immunology, 19, 222-232. https://doi.org/10.1038/s41590-018-0044-z
|
[2]
|
Li, X., Ramadori, P., Pfister, D., Seehawer, M., Zender, L. and Heikenwalder, M. (2021) The Immunological and Metabolic Landscape in Primary and Metastatic Liver Cancer. Nature Reviews Cancer, 21, 541-557.
https://doi.org/10.1038/s41568-021-00383-9
|
[3]
|
Kanwal, F., Kramer, J.R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P.A., Li, L., Desiderio, R., Thrift, A.P., Asch, S.M., Chu, J. and El-Serag, H.B. (2018) Risk of Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease. Gastroenterology, 155, 1828-1837. https://doi.org/10.1053/j.gastro.2018.08.024
|
[4]
|
Venerito, M., Link, A., Rokkas, T. and Malfertheiner, P. (2016) Gastric Cancer—Clinical and Epidemiological Aspects. Helicobacter, 21, 39-44. https://doi.org/10.1111/hel.12339
|
[5]
|
潘才豪. 原发性肝癌的中医治疗[C]//李俊德. 2013年中医、中西医结合防治肝癌、肝病高峰论坛论文集: 2013年卷, 2013: 121-131.
|
[6]
|
丁园园. 胃癌中医证型、证候及相关性研究[D]: [硕士学位论文]. 沈阳: 辽宁中医药大学, 2011.
|
[7]
|
张艳梅. 四君子汤治疗中医内科疾病脾胃气虚证的疗效[J]. 中医临床研究, 2022, 14(9): 100-102.
|
[8]
|
李紫瑞, 王坚, 王瑞平. 中医疏肝健脾法治疗肝癌的研究进展[J]. 现代中西医结合杂志, 2021, 30(21): 2383-2388.
|
[9]
|
郑蔚婵, 李辉, 龚雯婧. 复方皂角刺膏外敷治疗原发性肝癌重度癌性疼痛28例临床观察[J]. 湖南中医杂志, 2022, 38(10): 8-11.
|
[10]
|
Kong, D., Chen, H., Chen, W., Liu, S., Wang, H., Wu, T., Lu, H., Kong, Q., Huang, X. and Lu, Z. (2013) Gene Expression Profiling Analysis of Hepatocellular Carcinoma. European Journal of Medical Research, 18, Article No. 44.
https://doi.org/10.1186/2047-783X-18-44
|
[11]
|
Ghatak, S., Lalnunhlimi, S., Lalrohlui, F., Pautu, J.L., Zohmingthanga, J., Kunnumakkara, A.B. and Kumar, N.S. (2018) Novel AKT1 Mutations Associated with Cell-Cycle Abnormalities in Gastric Carcinoma. Personalized Medicine, 15, 79-86. https://doi.org/10.2217/pme-2017-0053
|
[12]
|
Deng, W., Hao, Q., Vadgama, J. and Wu, Y. (2021) Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer. Journal of Cancer Science and Clinical Therapeutics, 5, 134-153. https://doi.org/10.26502/jcsct.50790107
|
[13]
|
Castanhole-Nunes, M.M.U., Tunissiolli, N.M., Oliveira, A.R.C.P., Mattos, M.F., Galbiatti-Dias, A.L.S., Kawasaki- Oyama, R.S., Pavarino, E.C., Da Silva, R.F. and Goloni-Bertollo, E.M. (2022) MiR-612, miR-637, and miR-874 Can Regulate VEGFA Expression in Hepatocellular Carcinoma Cell Lines. Genes, 13, Article No. 282.
https://doi.org/10.3390/genes13020282
|
[14]
|
Zhou, M., Liu, X., Li, Z., Huang, Q., Li, F. and Li, C.-Y. (2018) Caspase-3 Regulates the Migration, Invasion and Metastasis of Colon Cancer Cells. International Journal of Cancer, 143, 921-930. https://doi.org/10.1002/ijc.31374
|
[15]
|
Ma, X.Y., Zhang, M., Fang, G., Cheng, C.J., Wang, M.K., Han, Y.M., Hou, X.T., Hao, E.W., Hou, Y.Y. and Bai, G. (2021) Ursolic Acid Reduces Hepatocellular Apoptosis and Alleviates Alcohol-Induced Liver Injury via Irreversible Inhibition of CASP3 in Vivo. Acta Pharmacologica Sinica, 42, 1101-1110.
https://doi.org/10.1038/s41401-020-00534-y
|
[16]
|
Wahlström, T. and Henriksson, M.A. (2015) Impact of MYC in Regulation of Tumor Cell Metabolism. Biochimica et Biophysica Acta (BBA)—Gene Regulatory Mechanisms, 1849, 563-569. https://doi.org/10.1016/j.bbagrm.2014.07.004
|
[17]
|
Ulrich, C.M., Whitton, J., Yu, J.-H., et al. (2005) PTGS2 (COX-2) −765G > C Promoter Variant Reduces Risk of Colorectal Adenoma among Nonusers of Nonsteroidal Anti-inflammatory Drugs. Cancer Epidemiology, Biomarkers & Prevention, 14, 616-619. https://doi.org/10.1158/1055-9965.EPI-04-0510
|
[18]
|
Lewis, A.M., Varghese, S., Xu, H. and Alexander, H.R. (2006) Interleukin-1 and Cancer Progression: The Emerging Role of Interleukin-1 Receptor Antagonist as a Novel Therapeutic Agent in Cancer Treatment. Journal of Translational Medicine, 4, Article No. 48. https://doi.org/10.1186/1479-5876-4-48
|
[19]
|
Chen, C.-Y., Chen, J., He, L. and Stiles, B.L. (2018) PTEN: Tumor Suppressor and Metabolic Regulator. Frontiers in Endocrinology, 9, Article 338. https://doi.org/10.3389/fendo.2018.00338
|
[20]
|
Davis, R.K. and Chellappan, S. (2008) Disrupting the Rb-Raf-1 Interaction: A Potential Therapeutic Target for Cancer. Drug News & Perspectives, 21, 331-335. https://doi.org/10.1358/dnp.2008.21.6.1246832
|
[21]
|
Duda, P., Akula, S.M., Abrams, S.L., Steelman, L.S., Martelli, A.M., Cocco, L., Ratti, S., Candido, S., Libra, M., Montalto, G., Cervello, M., Gizak, A., Rakus, D. and McCubrey, J.A. (2020) Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. Cells, 9, Article No. 1110. https://doi.org/10.3390/cells9051110
|
[22]
|
Papadopoli, D., Pollak, M. and Topisirovic, I. (2021) The Role of GSK3 in Metabolic Pathway Perturbations in Cancer. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1868, Article ID: 119059.
https://doi.org/10.1016/j.bbamcr.2021.119059
|
[23]
|
Ebrahim, A.S., Sabbagh, H., Liddane, A., Raufi, A., Kandouz, M. and Al-Katib, A. (2016) Hematologic Malignancies: Newer Strategies to Counter the BCL-2 Protein. Journal of Cancer Research and Clinical Oncology, 142, 2013-2022.
https://doi.org/10.1007/s00432-016-2144-1
|
[24]
|
Gaptulbarova, K.A., Tsyganov, M.M., Pevzner, A.M., Ibragimova, M.K. and Litviakov, N.V. (2020) NF-κB as a Potential Prognostic Marker and a Candidate for Targeted Therapy of Cancer. Experimental Oncology, 42, 263-269.
|
[25]
|
Stein, Y., Rotter, V. and Aloni-Grinstein, R. (2019) Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis. International Journal of Molecular Sciences, 20, Article No. 6197. https://doi.org/10.3390/ijms20246197
|
[26]
|
Duffy, M.J., O’Grady, S., Tang, M. and Crown, J. (2021) MYC as a Target for Cancer Treatment. Cancer Treatment Reviews, 94, Article ID: 102154. https://doi.org/10.1016/j.ctrv.2021.102154
|
[27]
|
Chen, H., Liu, H. and Qing, G. (2018) Targeting Oncogenic Myc as a Strategy for Cancer Treatment. Signal Transduction and Targeted Therapy, 3, Article No. 5. https://doi.org/10.1038/s41392-018-0008-7
|